Abstract:Purpose This study aimed to develop a radiomics signature for the preoperative prognosis prediction of isocitrate dehydrogenase (IDH)-wild-type glioblastoma (GBM) patients and to provide personalized assistance in the clinical decision-making for different patients. Materials and Methods A total of 142 IDH-wild-type GBM patients classified using the new classification criteria of WHO 2021 from two centers were included in the study and randomly divided into a training set and a test set. Firstly, their clinical characteristics were screened using univariate Cox regression. Then, the radiomics features were extracted from the tumor and peritumoral edema areas on their contrast-enhanced T1-weighted image (CE-T1WI), T2-weighted image (T2WI), and T2-weighted fluid-attenuated inversion recovery (T2-FLAIR) magnetic resonance imaging (MRI) images. Subsequently, inter- and intra-class correlation coefficient (ICC) analysis, Spearman’s correlation analysis, univariate Cox, and the least absolute shrinkage and selection operator (LASSO) Cox regression were used step by step for feature selection and the construction of a radiomics signature. The combined model was established by integrating the selected clinical factors. Kaplan–Meier analysis was performed for the validation of the discrimination ability of the model, and the C-index was used to evaluate consistency in the prediction. Finally, a Radiomics + Clinical nomogram was generated for personalized prognosis analysis and then validated using the calibration curve. Results Analysis of the clinical characteristics resulted in the screening of four risk factors. The combination of ICC, Spearman’s correlation, and univariate and LASSO Cox resulted in the selection of eight radiomics features, which made up the radiomics signature. Both the radiomics and combined models can significantly stratify high- and low-risk patients ( p < 0.001 and p < 0.05 for the training and test sets, respectively) and obtained good prediction consistency (C-index = 0.74–0.86). The calibration plots exhibited good agreement in both 1- and 2-year survival between the prediction of the model and the actual observation. Conclusion Radiomics is an independent preoperative non-invasive prognostic tool for patients who were newly classified as having IDH-wild-type GBM. The constructed nomogram, which combined radiomics features with clinical factors, can predict the overall survival (OS) of IDH-wild-type GBM patients and could be a new supplement to treatment guidelines.

A nomogram strategy for identifying the subclassification of IDH mutation and ATRX expression loss in lower-grade gliomas

Noninvasive Prediction of IDH1 Mutation and ATRX Expression Loss in Low‐Grade Gliomas Using Multiparametric MR Radiomic Features

Development of a nomogram based on radiomics and semantic features for predicting chromosome 7 gain/chromosome 10 loss in IDH wild-type histologically low-grade gliomas

A radiomics-clinical nomogram for preoperative prediction of IDH1 mutation in primary glioblastoma multiforme.

Radiomics Nomogram Building from Multiparametric MRI to Predict Grade in Patients with Glioma: A Cohort Study

Radiomics Strategy for Molecular Subtype Stratification of Lower-Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI.

A Radiomics Nomogram Based on Multiparametric MRI Might Stratify Glioblastoma Patients According to Survival.

Radiomics and Qualitative Features From Multiparametric MRI Predict Molecular Subtypes in Patients With Lower-Grade Glioma

Radiomics Analysis Based on Magnetic Resonance Imaging for Preoperative Overall Survival Prediction in Isocitrate Dehydrogenase Wild-Type Glioblastoma

Multicenter clinical radiomics–integrated model based on [18F]FDG PET and multi-modal MRI predict ATRX mutation status in IDH-mutant lower-grade gliomas

Predicting IDH Mutation Status in Low-Grade Gliomas Based on Optimal Radiomic Features Combined with Multi-Sequence Magnetic Resonance Imaging

Comprehensive multicentre retrospective analysis for predicting isocitrate dehydrogenase‐mutant lower‐grade gliomas

Multicenter clinical radiomics–integrated model based on [ 18 F]FDG PET and multi-modal MRI predict ATRX mutation status in IDH-mutant lower-grade gliomas

Multi-parameter MRI Based Radiomics Nomogram for Predicting Telomerase Reverse Transcriptase Promoter Mutation and Prognosis in Glioblastoma.

IDH mutation-specific radiomic signature in lower-grade gliomas.

Multicenter clinical radiomics-integrated model based on [<SUP>18</SUP>F]FDG PET and multi-modal MRI predict ATRX mutation status in IDH-mutant lower-grade gliomas

Quantitative MRI-based Radiomics for Noninvasively Predicting Molecular Subtypes and Survival in Glioma Patients

Prediction of the Molecular Subtype of IDH Mutation Combined with MGMT Promoter Methylation in Gliomas via Radiomics Based on Preoperative MRI

Image Omics Nomogram Based on Incoherent Motion Diffusion-Weighted Imaging in Voxels Predicts ATRX Gene Mutation Status of Brain Glioma Patients

Noninvasive Idh1 Mutation Estimation Based on A Quantitative Radiomics Approach for Grade Ii Glioma

Using Radiomics Based on Multicenter Magnetic Resonance Images to Predict Isocitrate Dehydrogenase Mutation Status of Gliomas.